Maintenance regimen of GM‐CSF with rituximab and lenalidomide improves survival in high‐risk B‐cell...
Maintenance regimen of GM‐CSF with rituximab and lenalidomide improves survival in high‐risk B‐cell lymphoma by modulating natural killer cells
About this item
Full title
Author / Creator
Sun, Shunrong , Fulati, Wulipan , Shen, Lin , Wu, Min , Huang, Zilan , Qian, Wensi , Chen, Pingping , Hu, Yingwei , Chen, Mingyue , Xu, Yu , Zhang, Hongdi , Ma, Jiexian and Xie, Yanhui
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
The treatment of high‐risk B‐cell lymphoma (BCL) remains a challenge, especially in the elderly.
Methods
A total of 83 patients (median age 65 years), who have achieved a complete response after induction therapy, were divided into two groups: R2 + GM‐CSF regimen (lenalidomide, rituximab, granulocyte‐macrophage colony‐stimulatin...
Alternative Titles
Full title
Maintenance regimen of GM‐CSF with rituximab and lenalidomide improves survival in high‐risk B‐cell lymphoma by modulating natural killer cells
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_9d89548b2759476bbbbc7754b6c08614
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9d89548b2759476bbbbc7754b6c08614
Other Identifiers
ISSN
2045-7634
E-ISSN
2045-7634
DOI
10.1002/cam4.5969
